Only 2 out of 10 are prescribed monotherapy for diabetes
By Kim, Jin-Gu | translator Alice Kang
22.10.07 06:18:54
가나다라
0
Korean Diabetes Association issues ‘2022 Diabetes Fact Sheet’...8 out of 10 receive combination therapy
Use of 3-or-more drug combination therapies rise from 32% to 38% in 5 years... use of dual combination therapy fall from 42% to 40% in the same period
Growth of DPP-4 inhibitors slowing amid rapid growth... SGLT-2i sales surge, sulfonylurea sales slow
The use of combination therapies in diabetes has been increasing further. Already, 8 of 10 patients are prescribed two or more drugs at once. In particular, the triple therapy combination regimen seems to be rapidly establishing its presence in the field.
By ingredient, DPP-4 inhibitor class drugs are still showing strength, but their growth is gradually slowing down. On the other hand, SGLT-2 inhibitor class drugs are gaining influence, while sulfonylurea class drugs are on a steady decline.
◆From dual to triple therapies…the diabetes treatment paradigm is shifting
The Korean Diabetes Association published a ‘2022 Diabetes Fact Sheet’ that contained the informatio
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)